ROS proto-oncogene 1 (ROS1) rearrangements are identified in 1–2% of NSCLC and in several other malignancies such as cholangiocarcinoma (CCA), glioblastoma, or colorectal cancer [66]. Here, ROS1 is linked to cholangiocarcinoma.